Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.

MLA

Kawakita, Daisuke, et al. “Survival Benefit of HER2-Targeted or Androgen Deprivation Therapy in Salivary Duct Carcinoma.” Therapeutic Advances in Medical Oncology, Sept. 2022, pp. 1–17. EBSCOhost, https://doi.org/10.1177/17588359221119538.

APA

Kawakita, D., Nagao, T., Takahashi, H., Kano, S., Honma, Y., Hirai, H., Saigusa, N., Akazawa, K., Tani, K., Ojiri, H., Tsukahara, K., Ozawa, H., Okami, K., Kondo, T., Togashi, T., Fushimi, C., Shimura, T., Shimizu, A., Okamoto, I., & Okada, T. (2022). Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Therapeutic Advances in Medical Oncology, 1–17. https://doi.org/10.1177/17588359221119538

Chicago

Kawakita, Daisuke, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, et al. 2022. “Survival Benefit of HER2-Targeted or Androgen Deprivation Therapy in Salivary Duct Carcinoma.” Therapeutic Advances in Medical Oncology, September, 1–17. doi:10.1177/17588359221119538.